Navigation Links
Ogden™ Soft Tissue Anchor System, Non-Sterile

ProductsOgden™ Soft Tissue Anchor System, Non-Sterile
Company USS Sports Medicine
Item Ogden™ Soft Tissue Anchor System, Non-Sterile
Features 
  • Cancellous threaded design
  • Self-Tapping
    • Description The USS Sports Medicine™ Ogden™ Non-Sterile Anchor is a nonabsorbable repair device to attach soft tissue to bone using sutures. The device is implanted into a prepared hole in the bone and is used to reattach damaged soft tissue. The anchors are manufactured from Titanium (6A14V ELI) alloy which conforms to ASTM (F136-92). The anchors are coated with Titanium Nitride (TiN) which conforms to (SAE AMS 2444). SUTURES Ogden Non-Sterile Anchors are indicated for use with multiple USP suture sizes. Selection of suture size should be based upon Anchor size, intended use and tensile strength requirements.
    Info USS Sports Medicine
    Customer Service: (800) 423-8772
    Web site: http://www.tycohealthcare.com

    Related medicine products :

    1. Ogden™ Soft Tissue Anchor System, Sterile Packs
    2. Straight Tissue Forceps
    3. Bishop-Harmon Straight Tissue Forceps
    4. Bishop-Harmon Curved Tissue Forceps
    5. Straight Tissue Forceps - Non-Magnetic
    6. Programmable Tissue Stainer TST 40, 115V, 60Hz, 100VA
    7. Programmable Tissue Stainer TST 40, 230V, 50Hz, 100VA
    8. Tissue-Tek DRS 2000
    9. Micro Tissue Forceps
    10. Micro Tissue Forceps with round handle
    11. LICOX Brain Tissue Oxygen Monitoring System
    The Shandon Linistat Linear Stainer is a compact answer to H&E frozen section protocols, with a footprint that fits on top of most cryostas to streamline workflow during frozen sectioning.
    The Shandon Finesse 315 low-cost precision microtome is ergonomically designed to consistently produce high quality routine paraffin sections without user strain or fatigue.
    The Shandon Cryotome E Cryostat model features an automated, precise electronic specimen advance system.
    The Shandon Pathcentre is a high-volume, totally enclosed tissue processor that allows complete user control and excellent continuous reagent agitation.
    Medicine Products:
    (Date:8/8/2008)...gnosis, less successful surgery, pair of studies f... -- The standard screening test for prostate cance...more vulnerable to the disease, and surgery is les...tudies found. , "Obese men are more likely to b...," said Dr. Stephen Freedland, an associate profes...
    (Date:8/8/2008)...A, Md., Aug. 8 /PRNewswire-FirstCall/ -- Hanger Or...nnounce that Moody,s Investors,Service revised its...itive",from "stable." Moody,s also affirmed Hanger...re pleased with the outlook change from Moody,s as...ten quarters," remarked George McHenry,Hanger,s C...
    (Date:8/7/2008)...ls of testosterone may be a key factor in spreadin... findings could help explain why males in a popula...ansmit disease., , Previous research has linked...tem suppression. Studies have shown that males, co...e, and account for a larger share of disease trans...
    (Date:8/7/2008)...urgh Tissue Engineering Initiative Marks 12th Year...p, PITTSBURGH, Aug. 7 /PRNewswire/ -- Twenty-four...ties, primarily across southwestern Pennsylvania,a...2th annual Summer,Internship Program of the Pittsb...l of the program is to expose greatly increased nu...
    Breaking Medicine News(10 mins):Health News:Obese Men Face Twin Threat From Prostate Cancer 2Health News:Testosterone key to disease transmission 2Health News:Thirty-seven College Students Participate in Regenerative Medicine Summer Research Program 2Health News:Thirty-seven College Students Participate in Regenerative Medicine Summer Research Program 3
    ... by researchers in the Institute of Preventive Med...casionally may be beneficial in countering dementi... that people who drank wine weekly or monthly were...tia, said that the findings are important because ...
    ...searchers of the Harvard Medical School, of more t...pamine antagonists, i.e. anti-psychotics, for eith...y have an increased risk of breast cancer. The stu...e taking dopamine antagonists and 55,000 women who...
    ...lished in an online issue of Nature Medicine by re...d a stunning discovery of a bold new type of vacci...ugs. The study which was carried// out on monkeys ...rmed and adapted in humans may signal a major new ...
    ... age people are now increasingly taking to gardeni...nt a rosy picture of beautiful gardens. Though gar...efits, researchers now suggest that enthusiastic//...f how to lift properly and do not have adequate pr...
    Other Medicine News:
    (Date:8/6/2008)... Milestone achievement triggers $15 million payme...axoSmithKline, CAMBRIDGE, Mass., Aug. 6 /PRNewswi...ngaged in the discovery and development of novel,t...nced the initiation of a,pivotal Phase 3 clinical ...e new onset type 1 diabetes. As a result of the in...
    (Date:8/5/2008)... National trial aims to help heart failure patien...lot risk and less blood damage than,earlier heart ...ewswire/ -- Anthony Shannon,made history on July 3...nited States to receive a new type of experimental...DuraHeart, it was implanted in his chest, and,conn...
    (Date:8/5/2008)... CAMBRIDGE, Mass., Aug. 5 /- Tolerx,...discovery and development of novel,therapies for t...d today,that Genentech, a collaborator, has moved ... monoclonal antibody, into a phase 1 clinical tria...trial is evaluating the,safety and tolerability of...
    (Date:8/5/2008)...irst Patients Treated Using Next Generation CyberK...CyberKnife Center, SUNNYVALE, Calif., Aug. 5 /PRN...: ARAY ), a global leader in the field of radiosu...e treated using the next,generation CyberKnife(R) ...alled at the Oklahoma CyberKnife, LLC in Tulsa, OK...
    Breaking Medicine Technology:Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial 2Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial 3Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial 4First U.S. Patient to Receive New Heart-Assist Device Doing Well After Surgery at University of Michigan 2First U.S. Patient to Receive New Heart-Assist Device Doing Well After Surgery at University of Michigan 3First U.S. Patient to Receive New Heart-Assist Device Doing Well After Surgery at University of Michigan 4Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 3New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 2New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 3New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 4Boston Scientific To Webcast Conference Call Discussing Second Quarter Financial Results 6259 1Boston Scientific To Webcast Conference Call Discussing Second Quarter Financial Results 6259 2American Telugu Association 26apos 3Bs Convention Attracts Over 10 000 People in the U S 6257 1American Telugu Association 26apos 3Bs Convention Attracts Over 10 000 People in the U S 6257 2American Telugu Association 26apos 3Bs Convention Attracts Over 10 000 People in the U S 6257 3American Telugu Association 26apos 3Bs Convention Attracts Over 10 000 People in the U S 6257 4Impact Systems Announces Completion of Successful Enterprise Content Migrations to Documentum 6 6255 1Impact Systems Announces Completion of Successful Enterprise Content Migrations to Documentum 6 6255 2Impact Systems Announces Completion of Successful Enterprise Content Migrations to Documentum 6 6255 3Why do people vote 3F Genetic variation in political participation 3781 1Why do people vote 3F Genetic variation in political participation 3781 2
    ...atients and physicians should find these data reas...irstCall/ --,GlaxoSmithKline said today that findi...one Evaluated for Cardiac Outcomes and,Regulation ...rial,designed specifically to determine cardiovasc...e 2 diabetes, adds further evidence to,the overall...
    ...W YORK--(BUSINESS WIRE)--Jun 5, 2007 - ERBITUX (ce...ody targeting the epidermal,growth factor receptor...stems Incorporated, was the focus of nine oral and... 43rd Annual Meeting,of the American Society of Cl...presentations showcased the extensive,clinical dev...
    Other Medicine Technology:Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 2Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 3Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 4Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 5Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 2Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 3Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 4Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 5Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 6Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 7Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 8Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 9Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 10